Related references
Note: Only part of the references are listed.Formulation, optimization, and characterization of whey protein isolate nanocrystals for celecoxib delivery
Muhammad Asim Farooq et al.
JOURNAL OF MICROENCAPSULATION (2021)
Liposome-based codelivery of celecoxib and doxorubicin hydrochloride as a synergistic dual-drug delivery system for enhancing the anticancer effect
Kamel S. Ahmed et al.
JOURNAL OF LIPOSOME RESEARCH (2020)
Hyaluronic Acid-Decorated Glycol Chitosan Nanoparticles for pH-Sensitive Controlled Release of Doxorubicin and Celecoxib in Nonsmall Cell Lung Cancer
Ruda Lee et al.
BIOCONJUGATE CHEMISTRY (2020)
Nanocarrier-Mediated Cytosolic Delivery of Biopharmaceuticals
Wei He et al.
ADVANCED FUNCTIONAL MATERIALS (2020)
Structural Modification of Nanomicelles through Phosphatidylcholine: The Enhanced Drug-Loading Capacity and Anticancer Activity of Celecoxib-Casein Nanoparticles for the Intravenous Delivery of Celecoxib
Liuli Xv et al.
NANOMATERIALS (2020)
PDK1 regulates the survival of the developing cortical interneurons
Yongjie Wei et al.
MOLECULAR BRAIN (2020)
Nanomedicine-based drug delivery towards tumor biological and immunological microenvironment
Jin Li et al.
ACTA PHARMACEUTICA SINICA B (2020)
Natural Ingredient-Based Polymeric Nanoparticles for Cancer Treatment
Ka Hong Wong et al.
MOLECULES (2020)
Targeting cancer with lactoferrin nanoparticles: recent advances
Anand K. Kondapi
NANOMEDICINE (2020)
Comparison of the benefits of celecoxib combined with anticancer therapy in advanced non-small cell lung cancer: A meta-analysis
Wei Zhang et al.
JOURNAL OF CANCER (2020)
Celecoxib With Neoadjuvant Chemotherapy for Breast Cancer Might Worsen Outcomes Differentially by COX-2 Expression and ER Status: Exploratory Analysis of the REMAGUS02 Trial
Anne-Sophie Hamy et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Redox-Responsive Dual Drug Delivery Nanosystem Suppresses Cancer Repopulation by Abrogating Doxorubicin-Promoted Cancer Stemness, Metastasis, and Drug Resistance
Jia Liu et al.
ADVANCED SCIENCE (2019)
Core-Shell Distinct Nanodrug Showing On-Demand Sequential Drug Release To Act on Multiple Cell Types for Synergistic Anticancer Therapy
Jinsheng Huang et al.
ACS NANO (2019)
A comprehensive evaluation of clinical efficacy and safety of celecoxib in combination with chemotherapy in metastatic or postoperative recurrent gastric cancer patients A preliminary, three-center, clinical trial study
Qinghong Guo et al.
MEDICINE (2019)
Design of colloidal drug carriers of celecoxib for use in treatment of breast cancer and leukemia
Melike Uner et al.
MATERIALS SCIENCE & ENGINEERING C-MATERIALS FOR BIOLOGICAL APPLICATIONS (2019)
The Effect of Biotinylated PAMAM G3 Dendrimers Conjugated with COX-2 Inhibitor (celecoxib) and PPARγ Agonist (Fmoc-L-Leucine) on Human Normal Fibroblasts, Immortalized Keratinocytes and Glioma Cells in Vitro
Lukasz Uram et al.
MOLECULES (2019)
pH and redox dual-responsive nanoparticles based on disulfide-containing poly(β-amino ester) for combining chemotherapy and COX-2 inhibitor to overcome drug resistance in breast cancer
Sipei Zhang et al.
JOURNAL OF NANOBIOTECHNOLOGY (2019)
Nanocrystals: A perspective on translational research and clinical studies
Maria Jarvis et al.
BIOENGINEERING & TRANSLATIONAL MEDICINE (2019)
Autophagy: novel applications of nonsteroidal anti-inflammatory drugs for primary cancer
Chen Yu et al.
CANCER MEDICINE (2018)
Celecoxib-Induced Self-Assembly of Smart Albumin-Doxorubicin Conjugate for Enhanced Cancer Therapy
Leilei Shi et al.
ACS APPLIED MATERIALS & INTERFACES (2018)
The effectiveness of cyclooxygenase-2 inhibitors and evaluation of angiogenesis in the model of experimental colorectal cancer
Hilal Gungor et al.
BIOMEDICINE & PHARMACOTHERAPY (2018)
Pulmonary absorption - estimation of effective pulmonary permeability and tissue retention of ten drugs using an ex vivo rat model and computational analysis
Johanna Eriksson et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2018)
Partially hydrolyzed guar gum as a potential prebiotic source
Deepak Mudgil et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES (2018)
Liposome encapsulation of doxorubicin and celecoxib in combination inhibits progression of human skin cancer cells
Sanjay Singh
International Journal of Nanomedicine (2018)
Stable and sustained release liposomal formulations of celecoxib: In vitro and in vivo anti-tumor evaluation
M. Matbou Riahi et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2018)
Enhancing the solubility and bioavailability of poorly water-soluble drugs using supercritical antisolvent (SAS) process
Sharif Md Abuzar et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2018)
Tailored Mesoporous Silica Nanoparticles for Controlled Drug Delivery: Platform Fabrication, Targeted Delivery, and Computational Design and Analysis
Xiaodong She et al.
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2018)
Liposomal Drug Delivery Systems and Anticancer Drugs
Temidayo O. B. Olusanya et al.
MOLECULES (2018)
Celecoxib suppresses proliferation and metastasis of pancreatic cancer cells by down-regulating STAT3/NF-kB and L1CAM activities
Chaohui Zuo et al.
PANCREATOLOGY (2018)
Efficacy and safety of COX-2 inhibitors for advanced non-small-cell lung cancer with chemotherapy: a meta-analysis
Ping Dai et al.
ONCOTARGETS AND THERAPY (2018)
Regulating the Golgi apparatus by co-delivery of a COX-2 inhibitor and Brefeldin A for suppression of tumor metastasis
Ru-Yi Yu et al.
BIOMATERIALS SCIENCE (2018)
Use of Polyamidoamine Dendrimers in Brain Diseases
Maria Florendo et al.
MOLECULES (2018)
Layer-by-layer gelatin/chondroitin quantum dots-based nanotheranostics: combined rapamycin/celecoxib delivery and cancer imaging
Ahmed S. AbdElhamid et al.
NANOMEDICINE (2018)
Lactoferrin-tagged quantum dots-based theranostic nanocapsules for combined COX-2 inhibitor/herbal therapy of breast cancer
Ahmed S. AbdElhamid et al.
NANOMEDICINE (2018)
Decorating protein nanospheres with lactoferrin enhances oral COX-2 inhibitor/herbal therapy of hepatocellular carcinoma
Mona A. Abdelmoneem et al.
NANOMEDICINE (2018)
Celecoxib in breast cancer prevention and therapy
Jieqing Li et al.
CANCER MANAGEMENT AND RESEARCH (2018)
Phase II study of celecoxib with docetaxel chemoradiotherapy followed by consolidation chemotherapy docetaxel plus cisplatin with maintenance celecoxib in inoperable stage III nonsmall cell lung cancer
Harminder Takhar et al.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2018)
Effects of Nonsteroidal Anti-Inflammatory Drugs at the Molecular Level
Caner Gunaydin et al.
EURASIAN JOURNAL OF MEDICINE (2018)
Nanoparticle-Based Celecoxib and Plumbagin for the Synergistic Treatment of Melanoma
Raghavendra Gowda et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Superiority of aromatase inhibitor and cyclooxygenase-2 inhibitor combined delivery: Hyaluronate-targeted versus PEGylated protamine nanocapsules for breast cancer therapy
Ahmed O. Elzoghby et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2017)
Multi-Reservoir Phospholipid Shell Encapsulating Protamine Nanocapsules for Co-Delivery of Letrozole and Celecoxib in Breast Cancer Therapy
Ahmed O. Elzoghby et al.
PHARMACEUTICAL RESEARCH (2017)
Celecoxib targets breast cancer stem cells by inhibiting the synthesis of prostaglandin E2 and down-regulating the Wnt pathway activity
Chaolin Huang et al.
ONCOTARGET (2017)
Preparation and evaluation of celecoxib nanosuspensions for bioavailability enhancement
Jiali He et al.
RSC ADVANCES (2017)
Devising new lipid-coated calcium phosphate/carbonate hybrid nanoparticles for controlled release in endosomes for efficient gene delivery
Yilun Wu et al.
JOURNAL OF MATERIALS CHEMISTRY B (2017)
Celecoxib induces cell death on non-small cell lung cancer cells through endoplasmic reticulum stress
Bomi Kim et al.
ANATOMY & CELL BIOLOGY (2017)
Preparation and Characterization of Celecoxib Agglomerated Nanocrystals and Dry Powder Inhalation Formulations to Improve its Aerosolization Performance
Sepideh Mardani et al.
PHARMACEUTICAL SCIENCES (2017)
Design, synthesis and bioactivities of Celecoxib analogues or derivatives
Shiyang Zhou et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2017)
Celecoxib induced apoptosis against different breast cancer cell lines by down-regulated NF-κB pathway
Guanying Wang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2017)
Celecoxib, a COX-2 Selective Inhibitor, Induces Cell Cycle Arrest at the G2/M Phase in HeLa Cervical Cancer Cells
Agustina Setiawati
Asian Pacific Journal of Cancer Prevention (2016)
Lipid Nanoparticles and their Application in Nanomedicine
Mehdi Rajabi et al.
CURRENT PHARMACEUTICAL BIOTECHNOLOGY (2016)
COX-2 inhibitors: a novel strategy in the management of breast cancer
Milosz Regulski et al.
DRUG DISCOVERY TODAY (2016)
Nebulizable colloidal nanoparticles co-encapsulating a COX-2 inhibitor and a herbal compound for treatment of lung cancer
Ramy Said-Elbahr et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2016)
Dendrimer-mediated approaches for the treatment of brain tumor
Nitin Dwivedi et al.
JOURNAL OF BIOMATERIALS SCIENCE-POLYMER EDITION (2016)
Chemoprevention of Colon Cancer through Inhibition of Angiogenesis and Induction of Apoptosis by Nonsteroidal Anti-Inflammatory Drugs
Preety Ghanghas et al.
JOURNAL OF ENVIRONMENTAL PATHOLOGY TOXICOLOGY AND ONCOLOGY (2016)
Celecoxib suppresses autophagy and enhances cytotoxicity of imatinib in imatinib-resistant chronic myeloid leukemia cells
Ying Lu et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2016)
Desirable Properties for 3rd Generation Cyclooxygenase-2 Inhibitors
Micky D. Tortorella et al.
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2016)
Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity
Santiago Zelenay et al.
CELL (2015)
Developing nanocrystals for cancer treatment
Yi Lu et al.
NANOMEDICINE (2015)
Advances and Challenges of Liposome Assisted Drug Delivery
Lisa Sercombe et al.
FRONTIERS IN PHARMACOLOGY (2015)
Ki67 is a promising molecular target in the diagnosis of cancer
Lian Tao Li et al.
MOLECULAR MEDICINE REPORTS (2015)
Formulation and optimization of celecoxib-loaded PLGA nanoparticles by the Taguchi design and their in vitro cytotoxicity for lung cancer therapy
Jaber Emami et al.
PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY (2015)
Letrozole dispersed on poly (vinyl alcohol) anchored maleic anhydride grafted low density polyethylene: A controlled drug delivery system for treatment of breast cancer
Akhtar Jahan Siddiqa et al.
COLLOIDS AND SURFACES B-BIOINTERFACES (2014)
Celecoxib regulates apoptosis and autophagy via the PI3K/Akt signaling pathway in SGC-7901 gastric cancer cells
Min Liu et al.
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE (2014)
A COX-2 inhibitor enhances the antitumor effects of chemotherapy and radiotherapy for esophageal squamous cell carcinoma
Gulbostan Yusup et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2014)
New celecoxib multiparticulate systems to improve glioblastoma treatment
M. Vera et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2014)
Antitumor effect of a selective COX-2 inhibitor, celecoxib, may be attributed to angiogenesis inhibition through modulating the PTEN/PI3K/Akt/HIF-1 pathway in an H22 murine hepatocarcinoma model
Wenwen Sui et al.
ONCOLOGY REPORTS (2014)
COX-2 Inhibitors and Gastric Cancer
Zhen Wang et al.
GASTROENTEROLOGY RESEARCH AND PRACTICE (2014)
COX-2 overexpression increases malignant potential of human glioma cells through Id1
Kaiming Xu et al.
ONCOTARGET (2014)
Protein Nanoparticles as Drug Delivery Carriers for Cancer Therapy
Warangkana Lohcharoenkal et al.
BIOMED RESEARCH INTERNATIONAL (2014)
Mesoporous carbon as a carrier for celecoxib: The improved inhibition effect on MDA-MB-231 cells migration and invasion
Wenquan Zhu et al.
ASIAN JOURNAL OF PHARMACEUTICAL SCIENCES (2014)
Celecoxib decreases growth and angiogenesis and promotes apoptosis in a tumor cell line resistant to chemotherapy
Carlos Rosas et al.
BIOLOGICAL RESEARCH (2014)
Correction: Optic Nerve Magnetisation Transfer Ratio after Acute Optic Neuritis Predicts Axonal and Visual Outcomes
Yejun Wang et al.
PLoS One (2013)
COX-independent mechanisms of cancer chemoprevention by anti-inflammatory drugs
Evrim Gurpinar et al.
FRONTIERS IN ONCOLOGY (2013)
Antitumor activity of the selective cyclooxygenase-2 inhibitor, celecoxib, on breast cancer in Vitro and in Vivo
Zhi-Jun Dai et al.
CANCER CELL INTERNATIONAL (2012)
Nanostructured lipid carriers system: Recent advances in drug delivery
Md Asif Iqbal et al.
JOURNAL OF DRUG TARGETING (2012)
Hyaluronic acid promotes angiogenesis by inducing RHAMM-TGFβ receptor interaction via CD44-PKCδ
Deokbum Park et al.
MOLECULES AND CELLS (2012)
Nanoparticles in targeted cancer therapy: mesoporous silica nanoparticles entering preclinical development stage
Jessica M. Rosenholm et al.
NANOMEDICINE (2012)
Prostaglandin E2 promotes intestinal tumor growth via DNA methylation
Dianren Xia et al.
NATURE MEDICINE (2012)
Celecoxib pathways: pharmacokinetics and pharmacodynamics
Li Gong et al.
PHARMACOGENETICS AND GENOMICS (2012)
Deconvoluting the context-dependent role for autophagy in cancer
Eileen White
NATURE REVIEWS CANCER (2012)
The potential of celecoxib-loaded hydroxyapatite-chitosan nanocomposite for the treatment of colon cancer
P. Venkatesan et al.
BIOMATERIALS (2011)
Lung Cancer Chemoprevention with Celecoxib in Former Smokers
Jenny T. Mao et al.
CANCER PREVENTION RESEARCH (2011)
Novel selective Cox-2 inhibitors induce apoptosis in Caco-2 colorectal carcinoma cell line
Reza Entezari Heravi et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2011)
Chemical and in vitro enzymatic stability of newly synthesized celecoxib lipophilic and hydrophilic amides
Amjad M. Qandil et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2011)
Celecoxib-induced apoptosis is enhanced by ABT-737 and by inhibition of autophagy in human colorectal cancer cells
Shengbing Huang et al.
AUTOPHAGY (2010)
Inhibiting NF-kappa B activation by small molecules as a therapeutic strategy
Subash C. Gupta et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS (2010)
NSAID Sulindac and Its Analog Bind RXRα and Inhibit RXRα-Dependent AKT Signaling
Hu Zhou et al.
CANCER CELL (2010)
Colon Tumor Cell Growth-Inhibitory Activity of Sulindac Sulfide and Other Nonsteroidal Anti-Inflammatory Drugs Is Associated with Phosphodiesterase 5 Inhibition
Heather N. Tinsley et al.
CANCER PREVENTION RESEARCH (2010)
Formulation, characterization and pulmonary deposition of nebulized celecoxib encapsulated nanostructured lipid carriers
Ram R. Patlolla et al.
JOURNAL OF CONTROLLED RELEASE (2010)
Antiangiogenic Activities of 2,5-Dimethyl-Celecoxib on the Tumor Vasculature
Jenilyn J. Virrey et al.
MOLECULAR CANCER THERAPEUTICS (2010)
The use of Cox-2 and PPAR gamma signaling in anti-cancer therapies
Lucia Knopfova et al.
EXPERIMENTAL AND THERAPEUTIC MEDICINE (2010)
Advantages of celecoxib nanosuspension formulation and transformation into tablets
Andrej Dolenc et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2009)
Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products
Jana Pardeike et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2009)
Sulindac sulfide selectively inhibits growth and induces apoptosis of human breast tumor cells by phosphodiesterase 5 inhibition, elevation of cyclic GMP, and activation of protein kinase G
Heather N. Tinsley et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer
Yogeshkumar Malam et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2009)
Expression of cyclic guanosine monophosphate-dependent protein kinase in metastatic colon carcinoma cells blocks tumor angiogenesis
In-Kiu Kwon et al.
CANCER (2008)
OSU-03012, a Novel Celecoxib Derivative, Induces Reactive Oxygen Species-Related Autophagy in Hepatocellular Carcinoma
Ming Gao et al.
CANCER RESEARCH (2008)
Antibody-modified liposomes for cancer chemotherapy
Vladimir Torchilin
EXPERT OPINION ON DRUG DELIVERY (2008)
Development of a rapidly dispersing tablet of a poorly wettable compound - formulation DOE and mechanistic study of effect of formulation excipients on wetting of celecoxib
Xiaorong He et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2008)
Comparative study of nanohydroxyapatite microspheres for medical applications
Alis Yovana Pataquiva Mateus et al.
JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A (2008)
Antiproliferative effect of sulindac in colonic neoplasia prevention: role of COOH-terminal Src kinase
Dhananjay P. Kunte et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Celecoxib-induced growth inhibition in SW480 colon cancer cells is associated with activation of protein kinase G
Jae-Won Soh et al.
MOLECULAR CARCINOGENESIS (2008)
Autophagy fights disease through cellular self-digestion
Noboru Mizushima et al.
NATURE (2008)
Nanostructured lipid carriers (NLC) in cosmetic dermal products
R. H. Mueller et al.
ADVANCED DRUG DELIVERY REVIEWS (2007)
Celecoxib induces apoptosis in COX-2 deficient human gastric cancer cells through Akt/GSK3β/NAG-1 pathway
Rul-Ping Pang et al.
CANCER LETTERS (2007)
Microscopic modes and free energies of 3-phosphoinositide-dependent kinase-1 (PDK1) binding with celecoxib and other inhibitors
Mohamed Diwan M. AbdulHameed et al.
JOURNAL OF PHYSICAL CHEMISTRY B (2006)
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome
Jerom Galon et al.
SCIENCE (2006)
Cyclooxygenase-2 inhibitors decrease vascular endothelial growth factor expression in colon cancer cells by enhanced degradation of Sp1 and Sp4 proteins
M Abdelrahim et al.
MOLECULAR PHARMACOLOGY (2005)
COX-2: A molecular target for colorectal cancer prevention
JR Brown et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity
DY Wei et al.
CANCER RESEARCH (2004)
Structure, regulation and function of PKB/AKT - a major therapeutic target
M Hanada et al.
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2004)
3-phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells
SK Kulp et al.
CANCER RESEARCH (2004)
Colonic drug delivery of 5-fluorouracil: an in vitro evaluation
VR Sinha et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2004)
Celecoxib induces apoptosis in cervical cancer cells independent of cyclooxygenase using NF-κB as a possible target
SH Kim et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2004)
Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-κB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation
Y Takada et al.
ONCOGENE (2004)
Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates activation of cigarette smoke-induced nuclear factor (NF)-κB by suppressing activation of IκBα kinase in human non-small cell lung carcinoma:: Correlation with suppression of cyclin D1, COX-2, and matrix metalloproteinase-9
S Shishodia et al.
CANCER RESEARCH (2004)
Effects of the selective COX-2 inhibitors celecoxib and rofecoxib on human vascular cells
E Niederberger et al.
BIOCHEMICAL PHARMACOLOGY (2004)
Comparative evaluation of cytotoxicity of a glucosamine-TBA conjugate and a chitosan-TBA conjugate
D Guggi et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2004)
Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells
XG Liu et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2004)
Differential effects of selective COX-2 inhibitors on cell cycle regulation and proliferation of glioblastoma cell lines
A Kardosh et al.
CANCER BIOLOGY & THERAPY (2004)
From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-pliosphoinositide-dependent protein kinase-1 inhibitors (Publication with Expression of Concern. See vol. 79, pg. 1716, 2019)
JX Zhu et al.
CANCER RESEARCH (2004)
Celecoxib: a potent cyclooxygenase-2 inhibitor in cancer prevention
K Kismet et al.
CANCER DETECTION AND PREVENTION (2004)
Nanotech approaches to delivery and imaging drug
SK Sahoo et al.
DRUG DISCOVERY TODAY (2003)
The dawning era of polymer therapeutics
R Duncan
NATURE REVIEWS DRUG DISCOVERY (2003)
Anti-angiogenic and apoptotic effects of metabolites of sulindac on chick embryo chorioallantoic membrane
S Elwich-Flis et al.
HYBRIDOMA AND HYBRIDOMICS (2003)
Multiple Roles of the PI3K/PKB (Akt) Pathway in Cell Cycle Progression
Jiyong Liang et al.
CELL CYCLE (2003)
Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27Kip1 by PKB/Akt-mediated phosphorylation in breast cancer
G Viglietto et al.
NATURE MEDICINE (2002)
Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line
S Arico et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Pharmacokinetic comparison of intravenous carbendazim and remote loaded carbendazim liposomes in nude mice
L Jia et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2002)
Discovery and design of retinoic acid receptor and retinoid X receptor class- and subtype-selective synthetic analogs of all-trans-retinoic acid and 9-cis-retinoic acid
MI Dawson et al.
CURRENT MEDICINAL CHEMISTRY (2002)
Peroxisome proliferator-activated receptor gamma (PPAR gamma) and its ligands: A review
KL Houseknecht et al.
DOMESTIC ANIMAL ENDOCRINOLOGY (2002)
Prostacyclin-dependent apoptosis mediated by PPARδ
T Hatae et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Access blood flow: Debate continues
WD Paulson et al.
SEMINARS IN DIALYSIS (2001)
Biodegradable polymeric nanoparticles as drug delivery devices
KS Soppimath et al.
JOURNAL OF CONTROLLED RELEASE (2001)
Prostacyclin-mediated activation of peroxisome proliferator-activated receptor δ in colorectal cancer
RA Gupta et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Solid lipid nanoparticles (SLN) for controlled drug delivery -: a review of the state of the art
RH Müller et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2000)
Share Paper
